Journal of Bioequivalence & Bioavailability

Maiuri AR, Wassink B, Turkus JD, Breier AB, Lansdell T, Kaur G, et al. (2017) Synergistic cytotoxicity from drugs and cytokines in vitro as an approach to classify drugs according to their potential to cause idiosyncratic hepatotoxicity: a proof-of-concept study. J Pharmacol Exper Therapeut 362:459-473.

Qiu Y, Li X, Duan JZ (2014) Influence of drug property and product design on in vitro–in vivo correlation of complex modified-release dosage forms. J Pharm Sci 103:507-516.

Solon LG, Guerra GB, Araújo AA, Barichello JM, Urizar JP, Soares LA (2010) Comparative bioavailability of a generic and two compounded naproxen sodium suspensions administered to rats.

Filist M, Szlaska I, Kaza M, Pawiński T (2016) Validated HPLC‐UV method for determination of naproxen in human plasma with proven selectivity against ibuprofen and paracetamol. Biomed Chromatogr 30:953-961.

Parthasarathi D, Gajendra C, Dattatreya A, Venkatesh YS (2011) Analysis of pharmacokinetic & pharmacodynamic models in oral and transdermal dosage forms. J Bioequiv Availab 3:268-276.

Nishant T, Sathish Kumar D, Arun Kumar PM (2011) Role of pharmacokinetic studies in drug discovery. J Bioequiv Availab 3:263-267.

Maiuri AR, Breier AB, Gora LF, Parkins RV, Ganey PE, Roth RA (2015) Cytotoxic synergy between cytokines and NSAIDs associated with idiosyncratic hepatotoxicity is driven by mitogen-activated protein kinases. Toxicol Sci 146:265-280.

Bioavailability and Interaction Potential of Atorvastatin and Losartan on Co-administration in Healthy Human Subjects

Vardhan V. Research and Reviews: Journal of Pharmacology and Toxicological Studies.

Choi Y, Lee S, Jang IJ, Yu KS (2018) Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Des Dev Ther 12:2301.

Singh R, Chakravorty A, Kumar P, Chaturvedi A, Singh R. Research and Reviews: Research Journal of Biology.

Herrera‑González S, Martínez‑Treviño DA, Aguirre‑Garza M, Gómez‑Silva M, Barrera‑Saldaña HA, León‑Cachón RB (2017) Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population. Biomed Reports 7:579-584.

Kumar HK, Reddy YN, Thriveni K, Bharathi DV, Venkateswarlu V (2012) Simultaneous Determination of Atorvastatin and Glimepiride by LC-MS/MS in Human Plasma and Its Application to a Pharmacokinetic Study. Am J Analyt Chem 2012.

Kumar S, Monif T, Khuroo A, Reyar S, Jain R, Singla AK, et al. Pharmacokinetic comparison and bioequivalence evaluation of losartan/hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Int J Clin Pharm Therapeut 52:39-54.

Prabhu P, Patravale V (2016) Dissolution enhancement of atorvastatin calcium by co-grinding technique. Drug Deliv Trans Res 6:380-391.

Parthasarathi D, Gajendra C, Dattatreya A, Sree Venkatesh Y (2011) Analysis of pharmacokinetic & pharmacodynamic models in oral and transdermal dosage forms. J Bioequiv Availab 3:268-276.

Nishant T, Sathish Kumar D, Arun Kumar PM (2011) Role of pharmacokinetic studies in drug discovery. J Bioequiv Availab 3:263-267.

León-Cachón RB, Ascacio-Martínez JA, Gamino-Peña ME, Cerda-Flores RM, Meester I, Gallardo-Blanco HL, et al. (2016) A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. BMC cancer 16:74.

Hotha KK, Yarramu NR, Kandibedala T, Dasari VB, Vobalaboina V (2012) Simultaneous determination of atorvastatin and glimepiride by LC-MS/MS in human plasma and its application to a pharmacokinetic study. Am J Analyt Chem 3:559.

Preparation and Application of Nanoemulsions in the Last Decade (2000–2010)